Tenderwize
Retour à la recherche

Open-house rebate agreements for Tocilizumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 05, 2026 · 68 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

Paper submissions require two original signed copies and timely receipt of the originals by the 10th of the month after...

Participation is limited to pharmaceutical companies and requires a signed declaration of reliability.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive supply/rebate agreement for Tocilizumab, ATC L04AC07.
  • Open-house model with identical, non-individually negotiable contract terms.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement for Tocilizumab (ATC L04AC07) offered by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract can start from 2025-01-01, runs until 2026-12-31, and applications can be submitted until 2026-11-05 11:00. No contract value is stated.

Risques

Paper submissions require two original signed copies and timely receipt of the originals by the 10th of the month after...

Participation is limited to pharmaceutical companies and requires a signed declaration of reliability.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreements for Tocilizumab

Single lot covering non-exclusive open-house rebate agreements for the pharmaceutical product Tocilizumab, ATC L04AC07. The lot is for supplies in Germany, with performance in Bavaria (DE212). The procedure is open-house, with no selection among bidders and identical contract terms for all eligible pharmaceutical companies. Lot information comes from structured data and the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Dec 2024 - Dec 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 05, 2026

Détails de la procédure

Date de publication
17 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
701022-2024

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30